| Patents for A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838) |
|---|
| 02/27/2001 | US6194212 Increasing gene expression by transducing eukaryotic cells with retrovirus vector having heterologous gene linked to regulatory sequence and scaffold attachment region of human interferon-beta gene, allowing cells to rest and express gene |
| 02/27/2001 | US6194208 Modified milk growth factor |
| 02/27/2001 | US6194207 Methods for the selective expansion of lymphocytes by in vitro cultivation |
| 02/27/2001 | US6194205 Multistep process using conditionally immortalized antigen-presenting cells which are engineered to express antigen of interest, adding leukocytic cells, and culturing mixture to activate the t cells |
| 02/27/2001 | US6194203 Capable of undergoing at least 60 passages in culture due to expression of viral gene; expresses metabolic markers and metabolic differentiation markers for non-immortalized cells; drug, metabolic, and toxicity screening of intestinal cells |
| 02/27/2001 | US6194191 Method for the production and purification of adenoviral vectors |
| 02/27/2001 | US6194138 Method for flushing blood cells using gelatin |
| 02/27/2001 | US6194137 Glassing erythrocyte arteries; immersing arteries in solutions of amplified concentration of freeze resistant liquids, cool arteries in liquid until it reaches the glass transition temperature of the arteries |
| 02/27/2001 | US6194136 Cryoprotective solutions comprising DMSO, PG, 2,3-butanediol,raffinose and PVP |
| 02/27/2001 | US6193891 Methods for the selective separation of organic components from biological fluids |
| 02/27/2001 | US6193577 Alternative medicine elements package |
| 02/27/2001 | CA2213775C Cancer metastasis inhibitor containing a streptococcus agalactiae ia type or ib type surface polysaccharide as a main ingredient |
| 02/27/2001 | CA2096654C Removal of antibodies from blood-derived compositions while retaining coagulation factors |
| 02/26/2001 | CA2281463A1 Composition comprising micronutrients in combination with prebiotics, probiotics, and synbiotics |
| 02/22/2001 | WO2001012831A2 Anti-bacterial and anti-viral compositions and methods |
| 02/22/2001 | WO2001012815A1 Coxsackie virus-derived vector system for gene transfer |
| 02/22/2001 | WO2001012811A1 C-type lectin transmembrane antigen expressed in human prostate cancer and uses thereof |
| 02/22/2001 | WO2001012810A1 Modified ciliary neurotrophic factor, method of making and methods of use thereof |
| 02/22/2001 | WO2001012805A1 Methods for diagnosis and treatment of human diseases including hypertension |
| 02/22/2001 | WO2001012785A1 Ex vivo generation of functional osteoclasts from bone marrow in a three-dimensional bioreactor |
| 02/22/2001 | WO2001012784A1 METHOD FOR TREATMENT OF β-HEMOGLOBINOPATHIES |
| 02/22/2001 | WO2001012775A2 25 human secreted proteins |
| 02/22/2001 | WO2001012674A1 Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof |
| 02/22/2001 | WO2001012670A1 Tgf-beta receptor polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | WO2001012236A2 Methods, compositions and kits for promoting recovery from damage to the central nervous system |
| 02/22/2001 | WO2001012235A2 Targeted artificial gene delivery |
| 02/22/2001 | WO2001012231A1 Method for delivery of therapeutic agents using a solution of dextrin |
| 02/22/2001 | WO2001012215A2 Protective antigen of epstein barr virus |
| 02/22/2001 | WO2001012207A1 Mechanically elongated neuronal cells and methods for producing and using these cells |
| 02/22/2001 | WO2001012206A2 Soy-glycine extracts and aromatase inhibitors for positively influencing collagen |
| 02/22/2001 | WO2001012201A1 Blood plasma replacement solution |
| 02/22/2001 | WO2001012164A1 Oral form of administration containing probiotic micro-organisms |
| 02/22/2001 | WO2000071737A3 Improved retroviral production by inhibition of the enveloppe cell receptor |
| 02/22/2001 | WO2000071156A3 New vaccine formulations-3 |
| 02/22/2001 | WO2000071155A3 New vaccine formulations - 2 |
| 02/22/2001 | WO2000063385A3 Nucleic acid immunization |
| 02/22/2001 | WO2000062788A3 Treatment of hypersensitivity reaction disorders |
| 02/22/2001 | WO2000049138A3 Pluripotential cells derived from embryonal teratocarcinoma cells and the nucleus of stomatic cells |
| 02/22/2001 | WO2000040614A3 Characterization of the soc/crac calcium channel protein family |
| 02/22/2001 | WO2000036107A3 Compositions and methods for therapy and diagnosis of ovarian cancer |
| 02/22/2001 | WO2000023100A8 Genes and proteins predictive and therapeutic for renal disease and associated disorders |
| 02/22/2001 | WO1999021005A3 Pharmaceutical grade st. john's wort |
| 02/22/2001 | DE19939095A1 Von Coxsackieviren abgeleitetes Vektorsystem für Gentransfer Of coxsackie-derived vector system for gene transfer |
| 02/22/2001 | DE19937361A1 Orale Darreichungsform The oral dosage form |
| 02/22/2001 | DE19936744A1 Phagozytenmodulatoren (insbesondere Phagozytenaktivatoren) zur Behandlung und/oder Prophylaxe thrombotischer, atherothrombotischer und/oder hämostaseologischer Erkrankungen Phagozytenmodulatoren (especially Phagozytenaktivatoren) for the treatment and / or prophylaxis of thrombotic, atherothrombotic and / or blood coagulation disorders |
| 02/22/2001 | CA2385431A1 Tgf-beta receptor polynucleotides, polypeptides, and antibodies |
| 02/22/2001 | CA2382251A1 Methods for diagnosis and treatment of human diseases including hypertension |
| 02/22/2001 | CA2382148A1 25 human secreted proteins |
| 02/22/2001 | CA2382090A1 Coxsackie virus-derived vector system for gene transfer |
| 02/22/2001 | CA2381798A1 Method for treatment of .beta.-hemoglobinopathies |
| 02/22/2001 | CA2381706A1 Ovarian cancer cell and myeloma cell surface glycoproteins, antibodies thereto, and uses thereof |
| 02/22/2001 | CA2380991A1 Protective antigen of epstein barr virus |
| 02/22/2001 | CA2380953A1 Methods, compositions and kits for promoting recovery from damage to the central nervous system |
| 02/22/2001 | CA2380940A1 Substances and agents for positively influencing collagen |
| 02/22/2001 | CA2380908A1 Plasma substitute composition |
| 02/22/2001 | CA2380517A1 Targeted artificial gene delivery |
| 02/22/2001 | CA2379940A1 Modified ciliary neurotrophic factor, method of making and methods of use thereof |
| 02/22/2001 | CA2378708A1 Method for delivery of therapeutic agents using a solution of dextrin |
| 02/22/2001 | CA2377415A1 An oral administration form |
| 02/21/2001 | EP1077254A2 Multiple mesodermal lineage differentiation potentials for adipose tissue-derived stromal cells and uses thereof |
| 02/21/2001 | EP1077253A1 Use of adipose tissue-derived stromal cells for chondrocyte differentiation and cartilage repair |
| 02/21/2001 | EP1076553A2 Pharmaceutical, hygienic and/or cosmetic compositions containing sea water and uses |
| 02/21/2001 | EP1076486A1 Culture of sessile marine animals |
| 02/21/2001 | EP0652968B1 Defective adenoviruses |
| 02/21/2001 | CN1285000A Equine infections anaemia virus (EIAV) based |
| 02/21/2001 | CN1284994A Use of bacteria endowed with arginine deiminase to induce apoptosis and/or reduce an inflammatory reaction and pharmaceutical or dietetic compositions containing such bacteria |
| 02/21/2001 | CN1284963A A method for the removal of causative agent(s) of transmissible spongiform |
| 02/21/2001 | CN1284886A Methods for quenching pathogen inactivators in biological materials |
| 02/21/2001 | CN1284376A Medicine for treating early-stage hepatocirrhosis and its preparation |
| 02/21/2001 | CN1284370A Chinese medicine for treating rheumatoid disease |
| 02/21/2001 | CN1284366A Preparation of life prolonging preparation |
| 02/21/2001 | CN1284365A Fracture treating plaster |
| 02/21/2001 | CN1284360A Tibeten medicine for treating hepatitis B and its preparation |
| 02/21/2001 | CN1284358A Men's tonic wine and its preparation |
| 02/21/2001 | CN1284357A Yichun wine and its preparation |
| 02/21/2001 | CN1284355A Medicine for treating cardiac and cerebral vascular diseases and its preparation |
| 02/21/2001 | CN1284354A Enteritis curing capsule |
| 02/21/2001 | CN1284349A Medicine pill for preventing and treating pathological seaility |
| 02/21/2001 | CN1284348A Liver protecting and pus drawing out ointment and its preparation |
| 02/21/2001 | CN1284346A Far infrared Gukangtie plaster |
| 02/21/2001 | CN1284341A Immune regulator of amino acid calcium from turtle shell and its preparation |
| 02/21/2001 | CN1284340A Production process of biologically active woodfrog fat capsule |
| 02/21/2001 | CN1284339A Acne-eliminating and beautifying toad cake ointment |
| 02/21/2001 | CN1284338A Asclerol extracting process from waste liquid after producing Heparin sodium |
| 02/21/2001 | CN1284337A Piles medicine |
| 02/21/2001 | CN1284302A Tonic beverage of Chinese woodfrog oil and its preparation |
| 02/21/2001 | CN1062304C Scorpoin and ant health-care spirit and preparation thereof |
| 02/21/2001 | CN1062182C Novel physiologically active substance |
| 02/21/2001 | CN1062180C Medicine for tonifying the kidney and strengthening Yang |
| 02/21/2001 | CN1062176C Oral liquid for curing cancer |
| 02/21/2001 | CN1062174C Method for preparing plant full natural nutrient solution and its product |
| 02/21/2001 | CN1062172C Medicine for treating cervical spondylopathy |
| 02/21/2001 | CN1062169C Tuberculosis medicine |
| 02/21/2001 | CN1062166C Chinese drugs preparation for promoting child intelligence development and preparation method of its solvable granules |
| 02/21/2001 | CN1062165C Eye ointment for curing myopia and amblyopia |
| 02/21/2001 | CN1062164C Oral medicine pill for curing myopia and amblyopia |
| 02/21/2001 | CN1062162C External use ointment for treatment of cutaneous pigmentation |
| 02/21/2001 | CN1062160C Drug for curing cerebral infarction |
| 02/21/2001 | CN1062151C Medicinal compsn. for treatment of heperosteogeny and its prepn. |
| 02/21/2001 | CN1062149C Marmot bone wine for curing rheumatism |